The number of PIC/S members is constantly growing. According to PIC/S, Hong Kong SAR’s Pharmacy and Poison Board has applied for PIC/S membership. Rapporteurs for this accession will be appointed at the next PIC/S Committee Meeting in Ottawa in October.
The Falsified Medicines Directive (FMD) has now been transposed into UK legislation and came into force on August 20, 2013. The FMD (Directive 2011/62/EU) introduces a series of measures to prevent the entry of falsified medicines and substandard raw materials into the legal supply chain, including stricter rules on the controls and inspections of producers of active pharmaceutical ingredients (APIs), intensified record-keeping requirements for wholesale distributors, and a common EU-wide logo to identify legal online pharmacies.
FDA is announcing the start of the Secure Supply Chain Pilot Program (SSCPP) in order to assist the Agency in its effort to prevent the importation of adulterated, misbranded, or unapproved drugs by allowing the FDA to focus its resources on imported drugs that fall outside the program and may pose risks.
The World Health Organization - supported by the IPEC Federation Member Groups - is currently in the process of revising and updating the „Good Trade and Distribution Practices for Pharmaceutical Starting Materials“ – WHO GTDP guide - which is open for comments for a restricted audience only until September 2013.
The draft is not to be displayed on any web site and will be presented to the WHO Expert Committee during the 48th meeting in October 2013. Following adoption, the IPEC Federation will update its own guide in line with that of WHO.
WHO: Current Projects
The US Food and Drug Administration's (FDA) has announced an initiative in the Center for Drug Evaluation and Research (CDER) involving the review of draft guidance documents issued before 2010. The CDER plans to determine their status, and to decide whether those guidances should be withdrawn, revised, or finalized with only minor changes. The new initiative was published in the latest edition of the Federal Register.
The Australian Therapeutic Goods Administration (TGA), part of the Department of Health and Ageing, has published an outline of its international engagement strategy for the next three years. It links current Australian government priorities for international engagement that are necessary to support effective therapeutic goods regulation with the TGA's business-as-usual activities and sets clear goals for international engagement activities.
The FDA published a draft on “Cosmetic Good Manufacturing Practices” in order to assist industry and stakeholders to identify the standards and issues that can affect the quality of cosmetic products. The document revises the “Cosmetic Good Manufacturing (GMP) Guidelines/Inspection Checklist” by updating it to set forth current practice and clarify certain topic areas based on recent experience.
The European Commission has published a draft of Annex 16 “Certification by a Qualified Person and Batch Release” of the EU GMP Guidelines. The Annex has been revised to reflect the globalisation of the pharmaceutical supply chains and the introduction of new quality control strategies. Furthermore, the ICH documents Q8, Q9 and Q10 were implemented.
COFEPRIS, Mexico’s Ministry of Health, through the Federal Commission for Protection against Health Risks has updated the requirements on GMP for active pharmaceutical ingredients comparable to those of the European Union. The new GMP requirements enter into force immediately and are mandatory for all establishments engaged in the manufacture and distribution of APIs.
With this standard, Mexico believes to have met the requirement for API exports to the EU under the EU Falsified Medicines Directive, which came into force on 2 July 2013.
So far, COFEPRIS has published a Spanish version of the document..
The WHO Expert Committee on Specifications for Pharmaceutical Preparations has published the Technical Report 981 which includes Annex 2, the WHO guidelines on quality risk management. QRM is the overall and continuing process of appropriately managing risks to product quality throughout the product's life-cycle in order to optimize its benefit–risk balance. It is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. It can be applied both proactively and retrospectively.
The U.S. Food and Drug Administration has announced that the USA is now a “listed country” with the European Commission (EC) so that U.S. companies need not obtain an export certificate form the FDA before shipping certain pharmaceutical products to Europe.